Nurexone Biologic Inc
F:J90
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nurexone Biologic Inc
Operating Income
Nurexone Biologic Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nurexone Biologic Inc
F:J90
|
Operating Income
-$5m
|
CAGR 3-Years
-238%
|
CAGR 5-Years
-123%
|
CAGR 10-Years
-53%
|
|
|
Enerflex Ltd
TSX:EFX
|
Operating Income
CA$310m
|
CAGR 3-Years
401%
|
CAGR 5-Years
21%
|
CAGR 10-Years
10%
|
|
|
T
|
TerraVest Industries Inc
TSX:TVK
|
Operating Income
CA$192.7m
|
CAGR 3-Years
40%
|
CAGR 5-Years
36%
|
CAGR 10-Years
24%
|
|
|
CES Energy Solutions Corp
TSX:CEU
|
Operating Income
CA$269.5m
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
42%
|
|
|
Secure Energy Services Inc
TSX:SES
|
Operating Income
CA$287m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
HydroGraph Clean Power Inc
CNSX:HG
|
Operating Income
-$6m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-113%
|
CAGR 10-Years
N/A
|
|
Nurexone Biologic Inc
Glance View
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles (EV)-based technology drug platform. The company is headquartered in Edmonton, Alberta. The company went IPO on 2012-05-08. The firm is developing a biological extracellular vesicles (EV)-based technology drug platform. The technology drug platform offers treatment for reversing paralysis and improving the life of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified small interfering RNA (siRNA) sequence. Its technology is used to treat various conditions, such as spinal cord injury, traumatic brain injury, and other brain and neurological indications. The firm also has developed exosome manufacturing process. The company is also focused on exosome research, management of clinical studies and commercialization of the technology for different indications, not limited to the central nervous system.
See Also
What is Nurexone Biologic Inc's Operating Income?
Operating Income
-5m
USD
Based on the financial report for Dec 31, 2024, Nurexone Biologic Inc's Operating Income amounts to -5m USD.
What is Nurexone Biologic Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-53%
Over the last year, the Operating Income growth was -37%. The average annual Operating Income growth rates for Nurexone Biologic Inc have been -238% over the past three years , -123% over the past five years , and -53% over the past ten years .
